Robust equity market conditions and sustained investor demand for AI-adjacent issuers have kept the 2026 IPO window open through September, with U.S. proceeds already exceeding $250 billion year-to-date across dozens of deals and additional sizable listings scheduled for the final quarter. Recent pricing activity—including Oura’s planned $2.1 billion Nasdaq debut and multiple biotech and acquisition-vehicle offerings—reflects continued pipeline momentum, while confidential filings from Anthropic and OpenAI position potential mega-listings as key swing factors before year-end. Stable Treasury yields, healthy corporate earnings growth, and post-SpaceX precedent support trader expectations that multiple high-profile names could clear regulatory and market hurdles in the remaining months, though execution risks tied to valuation debates and any late-year macro volatility continue to influence implied probabilities across individual company contracts.